Company

Biotissue Technologies SAS

5, rue Henri Desbruères – Bâtiment 7
91000 EVRY-COURCOURONNES

Email : info@biotissue.tech

Sebastian SCHROEDER : Président & CEO
Samia LAGHRABLI : Directrice opérationnelle (COO)

#Healthtech #Biomaterials

Regenerative medicine
Implant
Biology
Cell Therapy
Materials Science

Programs:

Field of activity

BioTissue’s innovation lies in its range of three-dimensional, fully resorbable, and mechanically stable implants, as well as its cell therapy solutions. These implants create an optimal environment for the patient’s own cells, enabling the reconstruction and long-lasting regeneration of damaged tissues.

BACKGROUND

BioTissue was formed by a double spin off from the Charité Universitätsmedizin Berlin and the University Hospital of Freiburg. Its activities are concentrated at its sites in Geneva (headquarters), Berlin (Charité Mitte Campus) and since 2025 at Genopole where its subsidiary BioTissue Technologies SAS has been established, to intensify its industrial production and launch its commercialization on an international scale.

DESCRIPTION

Its flagship product, Chondrotissue, is a resorbable synthetic implant designed for the regeneration of joint cartilage. Placed arthroscopically over the damaged area, it creates an optimal (stable, 3D) environment that allows the patient’s cells to rebuild functional and durable cartilage. BioTissue also possesses a unique cell therapy platform, “Bioseed,” for various medical indications in tissue regeneration.

ACCOMPLISHMENTS / PARTNERSHIPS / HIGHLIGHTS

The Chondrotissue solution has already enabled the treatment of 6,500 patients in Europe. BioTissue Technologies SAS plans to ramp up production in 2026: a new production line has been installed and qualified in a highly secure environment at Genopole, with the aim of commercial deployment in Europe and Asia.

COLLABORATIONs SOUGHT

The company is seeking financial partners to support its industrial scaling up.

More Information
Strenghts:
- BioTissue’s patented innovation addresses a significant need in two segments:
  1/ Sports medicine
  2/ Treating age-related degenerative conditions
- Global market
- Scientific proof of concept: CE certification in Europe, FDA Breakthrough Device

Genopole Companies

#Biothérapies #Healthtech

In the same field

ALGENSCRIBE

Algenscribe develops molecular biology tools designed to significantly increase the efficiency of gene replacement (insertion of a therapeutic gene into its native locus), which remains one of the major bottlenecks in gene editing. The platform also improves the quality of gene editing.

Discover

Synaptys neuroscience

SYNAPTYS neuroscience is developing SYS-0108, the first Neuro-Synergistic Conjugate for Alzheimer’s disease—a disruptive, patented innovation inspired by combination strategies used in oncology.

Discover

VRAI Heart

VRAI-Heart offers unprecedented intuitive, real-time navigation, enabling complete immersion in an extremely precise heart model, personalized for each patient, thanks to a combination of virtual reality and artificial intelligence.

Discover

Orinova

is developing a breakthrough innovation in oncology with a patented nanomedicine incorporating a unique dual therapy: a chemotherapy molecule combined with gold nanoparticles.

Discover

AGS Therapeutics

AGS Therapeutics is a biotech company pioneering the use of microalgae extracellular vesicles (MEVs) as a universal delivery system for innovative therapeutics, vaccines and gene therapies.

Discover